01.09.25 -- Survey Findings: How Are IDMP Readiness Efforts Progressing?

We’re ready to help usher your next drug into market! 2025’s first Outsourced Pharma Capacity Update provides a unique, virtual experience and the details necessary to find a CDMO for your specific timeline, volume, and production needs. Join us the last week of January as we draw the curtains on the industry’s best and give you complimentary VIP access to the resources available to support your success. Learn more and register to save your seat!

A report from WittKieffer's Global Life Sciences provides a macro analysis of the executives that helm today’s CDMOs. When choosing a CDMO, are you adequately assessing their senior executives? Do they inspire confidence in being a well-governed and operated entity?

Explore some of the more challenging aspects surrounding in-use testing for parenteral delivery along with potential strategies to address these issues.

Learn the current innovations and trends in the development of ADCs focusing on three main aspects: linker technology, drug payloads, and manufacturing.

Examine the impact of deep cold storage on functional performance, sub-visible particle levels, and container closure integrity in prefillable syringes.

Discover how a purification development platform with a mixed-mode chromatography step enabled Igyxos Biotherapeutics to streamline clinical trial supply and produce high-quality material efficiently.

Rapid development of high-quality cell lines is vital to biomanufacturing projects. How developers approach the fundamental steps can define their core biologics capabilities and keep projects on track.

Here, the authors explain how to identify potential product failure points and design robust formulations and processes for lyophilized products backed by solid data.

Product quality assessments revealed that a customer’s therapeutic protein had a range of hydrophobic HCPs. Review a solution that took an alternative approach by utilizing cell line engineering.

This study develops a serum-free suspension MDCK cell line optimized for isolating human influenza viruses from clinical samples and scalable vaccine production.

In this video, we provide information about our new facility expansions, enhanced filling capacity, and advanced packaging capabilities designed to support and elevate drug development projects.

We ensure that clients can tap into the knowledge and resources of Recipharm's experts worldwide, enabling them to navigate complex regulatory landscapes and penetrate new markets.

Utilize our Japan team's comprehensive services, including primary and secondary clinical packaging and labeling, comparator sourcing, cold chain storage, and local and global distribution.

Our San Diego facility features a high-speed, multi-purpose fill-finish line for vials, syringes, and cartridges, capable of fulfilling your injectable manufacturing needs.